Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
2022-500881-80-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat with Placebo (2 arms). Primary endpoint: Time to First Occurrence of Composite Endpoint of Cardiovascular Death or Heart Failure Hospitalization. Started Apr 2023; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2022-500881-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500881-80-00.